PXS-4728 (A)

Phase 2Small molecule

SSyntara

PXS-4728 (A) is one of 11 small molecule programs targeting Sleep. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SleepActive, not recruiting

SleepPhase 2

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Sleep

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

4 2

Ambien

PPurdue Pharma LP

Approved

4 3

Hetlioz

VVanda Pharmaceuticals

Phase 3

2 4

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 5

Mounjaro

Eli Lilly

Preclinical

1 6

Anerem

AAcacia Pharma Ltd

Preclinical

2 7

Ketalar

PXS-4728 (A)

1 9

Rhofade

KKenvue Brands

Preclinical

1 10

Capromorelin

UUniversity of Aarhus

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sleep1 trial

Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

Active, not recruiting·SSyntara·Phase 2·NCT05904717·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PXS-4728 (A). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PXS-4728 (A) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PXS-4728 (A). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Syntara company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSyntara

PXS-4728 (A)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sleep1 trial

References

Drug Info

Quick Facts

Related News